Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#91 / 200 Total
DDC - DDC Enterprise Ltd. - Stock Price Chart
TickerDDC [AMEX]
CompanyDDC Enterprise Ltd.
CountryHong Kong
IndustryPackaged Foods
Market Cap21.91MEPS (ttm)-1.19
P/E-EPS this Y72.30%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.79EPS next 5Y-
P/B-EPS Q/Q22.90%
Dividend-Sales Q/Q25.70%
Insider Own29.63%Inst Own6.79%
Insider Trans0.00%Inst Trans-
Short Float0.44%Earnings-
Analyst Recom2.00Target Price5.20
Avg Volume1.85M52W Range0.50 - 8.50
DDC Enterprise Limited provides ready-to-heat, ready-to-cook, and ready-to-eat plant-based meal products in Hong Kong and internationally. It also provides marketplace, advertising, and content distribution and placement services to third-party brands and products. The company was incorporated in 2012 and is based in Sheung Wan, Hong Kong.
TTOO - T2 Biosystems Inc - Stock Price Chart
CompanyT2 Biosystems Inc
IndustryDiagnostics & Research
Market Cap88.53MEPS (ttm)-16.49
P/E-EPS this Y80.77%
Forward P/E-EPS next Y62.06%
PEG-EPS past 5Y68.62%
P/S12.33EPS next 5Y-
P/B-EPS Q/Q97.98%
Dividend-Sales Q/Q-0.82%
Insider Own64.75%Inst Own1.13%
Insider Trans0.00%Inst Trans12.01%
Short Float5.36%EarningsMay 06/a
Analyst Recom3.00Target Price3.00
Avg Volume329.48K52W Range2.60 - 70.00
T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CR Group L.P.10% OwnerSep 28 '23Sale0.167,148,9451,125,9590Sep 29 04:30 PM
CR Group L.P.10% OwnerSep 27 '23Sale0.195,981,2021,145,998571,796Sep 29 04:30 PM
CR Group L.P.10% OwnerSep 26 '23Sale0.205,392,9201,082,3591,050,192Sep 28 04:30 PM
CR Group L.P.10% OwnerSep 25 '23Sale0.25250,00062,5001,481,535Sep 27 05:53 PM
CR Group L.P.10% OwnerSep 22 '23Sale0.265,079,3441,314,5341,501,531Sep 26 05:15 PM
GILD - Gilead Sciences, Inc. - Stock Price Chart
TickerGILD [NASD, NDX, S&P 500]
CompanyGilead Sciences, Inc.
IndustryDrug Manufacturers - General
Market Cap85.33BEPS (ttm)0.36
P/E190.94EPS this Y-43.83%
Forward P/E9.54EPS next Y90.27%
PEG35.46EPS past 5Y1.55%
P/S3.11EPS next 5Y5.38%
P/B4.87EPS Q/Q-517.48%
Dividend4.53%Sales Q/Q5.66%
Insider Own0.09%Inst Own85.68%
Insider Trans-2.22%Inst Trans0.85%
Short Float2.04%EarningsApr 25/a
Analyst Recom2.16Target Price82.17
Avg Volume7.16M52W Range62.07 - 87.86
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Parsey MerdadChief Medical OfficerApr 01 '24Sale72.962,000145,92096,304Apr 02 06:38 PM
Parsey MerdadChief Medical OfficerFeb 29 '24Sale72.748,230598,62492,706Feb 29 06:35 PM
Parsey MerdadChief Medical OfficerFeb 28 '24Sale73.182,000146,360100,936Feb 29 06:35 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
SSP - E.W. Scripps Co. - Stock Price Chart
CompanyE.W. Scripps Co.
Market Cap186.16MEPS (ttm)-11.61
P/E-EPS this Y437.38%
Forward P/E-EPS next Y-128.73%
PEG-EPS past 5Y-
P/S0.08EPS next 5Y10.00%
P/B0.25EPS Q/Q59.57%
Dividend-Sales Q/Q6.38%
Insider Own28.51%Inst Own68.01%
Insider Trans0.06%Inst Trans1.63%
Short Float7.17%EarningsMay 09/a
Analyst Recom2.60Target Price9.62
Avg Volume1.26M52W Range1.96 - 11.02
The E.W. Scripps Co. engages in television and newspaper publishing. It operates through the following business segments: Local Media, Scripps Networks, and Other. The Local Media segment consists of local broadcast television stations and their related digital operations. The Scripps Networks segment consists of national television networks. The company was founded in 1878 and is headquartered in Cincinnati, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scagliotti R. Michael10% OwnerMar 13 '24Buy4.162,3009,56841,747Mar 15 04:05 PM
Barmonde Charles L.DirectorFeb 29 '24Buy4.2810,50044,970642,401Mar 01 04:09 PM
Scripps John Patrick10% OwnerFeb 28 '24Buy4.502,1009,4603,236Mar 01 05:57 PM
Scripps John Patrick10% OwnerNov 14 '23Buy7.306704,8911,136Nov 15 09:03 PM
O'Brian KatePresident, Scripps NewsAug 14 '23Sale9.445,14448,576840Aug 15 09:26 AM
GREE - Greenidge Generation Holdings Inc - Stock Price Chart
CompanyGreenidge Generation Holdings Inc
IndustryCapital Markets
Market Cap31.88MEPS (ttm)-3.58
P/E-EPS this Y49.71%
Forward P/E-EPS next Y2.34%
PEG-EPS past 5Y36.24%
P/S0.43EPS next 5Y-
P/B-EPS Q/Q-171.68%
Dividend-Sales Q/Q27.55%
Insider Own30.42%Inst Own9.84%
Insider Trans-1.09%Inst Trans7.86%
Short Float2.15%EarningsMay 02/a
Analyst Recom1.00Target Price5.00
Avg Volume204.21K52W Range2.17 - 9.26
Greenidge Generation Holdings, Inc. owns and operates a vertically integrated Bitcoin mining and power generation facility. It engages in the mining of Bitcoin and contributes to the security and transactability of the Bitcoin ecosystem while concurrently meeting the power needs of homes and businesses. The company was founded in 2014 and is headquartered Dresden, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Irwin DalePresidentMay 28 '24Sale2.818,77724,63970,962May 29 05:35 PM
Irwin DalePresidentMay 20 '24Sale2.5525,00063,79779,739May 23 06:22 PM
Irwin DalePresidentFeb 28 '24Sale4.185,64623,600104,739Mar 01 02:36 PM
Kovler JordanChief Executive OfficerFeb 20 '24Buy3.872,0007,74012,000Feb 21 02:46 PM
Kovler JordanChief Executive OfficerFeb 16 '24Buy4.071,5006,11210,000Feb 21 02:46 PM
ALAR - Alarum Technologies Ltd ADR - Stock Price Chart
CompanyAlarum Technologies Ltd ADR
IndustrySoftware - Infrastructure
Market Cap203.73MEPS (ttm)-1.40
P/E-EPS this Y935.71%
Forward P/E214.00EPS next Y-88.03%
PEG-EPS past 5Y78.06%
P/S6.97EPS next 5Y-
P/B11.23EPS Q/Q207.51%
Dividend-Sales Q/Q47.49%
Insider Own4.54%Inst Own7.18%
Insider Trans0.00%Inst Trans-26.90%
Short Float4.66%EarningsMay 21/b
Analyst Recom1.00Target Price35.00
Avg Volume357.20K52W Range2.07 - 40.94
Alarum Technologies Ltd. engages in the provision of zero trust access solutions. It operates through the Enterprise Internet Access and Consumer Internet Access segments. The Enterprise Internet Access segment focuses on solutions provided through the company's wholly owned subsidiary NetNut Ltd. and enable customers to collect data anonymously at any scale from any public sources over the web using a unique hybrid network. The Consumer Internet Access segment offers a wide security blanket against ransomware, viruses, phishing, and other online threats as well as a powerful, secured and encrypted connection, masking the customers online activity, and keeping them safe from hackers. The company was founded by Avi Ben-David, Daniel Shachar, Amir Mizhar, and Eitan Bremler in October 1989 and is headquartered in Herzliya, Israel.
VIGL - Vigil Neuroscience Inc - Stock Price Chart
CompanyVigil Neuroscience Inc
Market Cap157.46MEPS (ttm)-2.12
P/E-EPS this Y9.96%
Forward P/E-EPS next Y-0.38%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.52EPS Q/Q2.59%
Dividend-Sales Q/Q-
Insider Own58.66%Inst Own39.10%
Insider Trans0.00%Inst Trans28.17%
Short Float5.66%EarningsMay 07/a
Analyst Recom1.50Target Price16.75
Avg Volume168.13K52W Range2.47 - 11.11
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Magovcevic-Liebisch IvanaPresident and CEONov 20 '23Buy3.754,00015,000207,687Nov 20 06:34 PM
ABL - Abacus Life Inc - Stock Price Chart
TickerABL [NASD]
CompanyAbacus Life Inc
IndustryInsurance - Life
Market Cap624.12MEPS (ttm)0.03
P/E347.15EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S8.03EPS next 5Y-
P/B3.72EPS Q/Q-113.33%
Dividend-Sales Q/Q129.12%
Insider Own96.78%Inst Own0.87%
Insider Trans0.00%Inst Trans-24.74%
Short Float18.09%EarningsMay 29
Analyst Recom1.00Target Price16.00
Avg Volume27.14K52W Range5.47 - 13.25
Abacus Life, Inc. is an integrated alternative asset manager, which engages in the business of investing in inforce life insurance products. The firm is involved in purchasing outstanding life insurance policies to connect buyers and sellers through an origination process. It operates through the following segments: Portfolio Servicing, Active Management, and Originations. The Portfolio servicing segment offers policy services to customers on a contract basis. The Active Management segment is involved in buying, selling, and trading policies and maintaining policies through to death benefit. The Origination segment originates life insurance policy settlement contracts as a licensed life settlement provider on behalf of third-party institutional investors interested in investing in the life settlement asset class. The company was founded by Matthew Ganovsky, Kevin Scott Kirby, and Todd Sean McNealy on May 22, 2020 and is headquartered in Orlando, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gusky Adam SamuelDirectorNov 17 '23Buy6.025,00030,10022,718Nov 20 06:57 PM
Gusky Adam SamuelDirectorNov 16 '23Buy6.167,20044,38117,718Nov 20 06:57 PM
McNealy SeanCo-Founder and PresidentNov 16 '23Buy6.173001,85112,593,550Nov 20 06:15 PM
Schulte Mary BethDirectorAug 23 '23Buy7.7313,000100,50813,000Aug 24 04:04 PM
GAU - Galiano Gold Inc - Stock Price Chart
TickerGAU [AMEX]
CompanyGaliano Gold Inc
Market Cap437.10MEPS (ttm)0.06
P/E29.86EPS this Y96.63%
Forward P/E2.60EPS next Y180.67%
PEG-EPS past 5Y-
P/S13.79EPS next 5Y-
P/B1.90EPS Q/Q-153.97%
Dividend-Sales Q/Q-
Insider Own24.17%Inst Own47.81%
Insider Trans0.00%Inst Trans-
Short Float0.34%EarningsMay 02/a
Analyst Recom1.75Target Price2.46
Avg Volume1.62M52W Range0.52 - 1.90
Galiano Gold, Inc. engages in the acquisition and exploration of mineral resources. It holds interest in the Asanko Gold Mine project. It operates through the Canada and West Africa geographical segments. The company was founded by Ivan James Bebek and Shawn Kristen Wallace on September 23, 1999, and is headquartered in Vancouver, Canada.
KYTX - Kyverna Therapeutics Inc. - Stock Price Chart
CompanyKyverna Therapeutics Inc.
Market Cap346.25MEPS (ttm)-
P/E-EPS this Y96.08%
Forward P/E-EPS next Y-17.45%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.96EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own55.45%Inst Own38.56%
Insider Trans9.44%Inst Trans-
Short Float15.22%EarningsMay 14/a
Analyst Recom1.00Target Price42.75
Avg Volume567.47K52W Range6.75 - 35.06
Jun-20-24 08:55AM Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Karen MarieChief Technology OfficerJun 06 '24Option Exercise4.429,63642,5919,636Jun 10 06:56 PM
Jones Ryan AlexanderChief Financial OfficerMay 28 '24Option Exercise0.7318,01613,15243,950May 29 04:33 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
Northpond Ventures III GP, LLCFormer 10% OwnerFeb 12 '24Buy22.00450,0009,900,000450,000Feb 12 05:51 PM
Bain Capital Life Sciences Inv10% OwnerFeb 12 '24Buy22.00450,0009,900,0003,163,868Feb 14 05:26 PM